HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 216 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $843,227 | -10.3% | 22,074 | +0.6% | 0.01% | 0.0% |
Q2 2023 | $939,654 | +13.3% | 21,944 | +1.0% | 0.01% | 0.0% |
Q1 2023 | $829,372 | -32.2% | 21,717 | 0.0% | 0.01% | -87.1% |
Q4 2022 | $1,223,362 | -25.9% | 21,717 | -48.0% | 0.06% | +226.3% |
Q3 2022 | $1,652,000 | -10.1% | 41,782 | +0.0% | 0.02% | +18.8% |
Q2 2022 | $1,838,000 | +10.3% | 41,765 | -0.0% | 0.02% | +23.1% |
Q1 2022 | $1,666,000 | -0.9% | 41,772 | -0.1% | 0.01% | 0.0% |
Q4 2021 | $1,681,000 | -50.4% | 41,810 | -49.8% | 0.01% | -40.9% |
Q3 2021 | $3,386,000 | +78.8% | 83,234 | +99.6% | 0.02% | +29.4% |
Q2 2021 | $1,894,000 | +9.0% | 41,700 | 0.0% | 0.02% | 0.0% |
Q1 2021 | $1,738,000 | +618.2% | 41,700 | +167.8% | 0.02% | +325.0% |
Q3 2019 | $242,000 | -9.7% | 15,570 | -0.1% | 0.00% | -20.0% |
Q2 2019 | $268,000 | +9.4% | 15,587 | +2.5% | 0.01% | 0.0% |
Q1 2019 | $245,000 | +8.4% | 15,210 | -1.6% | 0.01% | 0.0% |
Q4 2018 | $226,000 | – | 15,465 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
2Xideas AG | 416,586 | $23,703,743 | 2.51% |
Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |